Stanford’s New Leap in Personalized Medicine and Trials
The forefront of personalized medicine is dramatically reshaped by advancements in biomarker discovery and digital health technologies (DHTs) –...
Pfizer’s Phase 3 Trial Shows Positive Survival in DLBCL
Pfizer Inc. has announced promising Phase 3 study results for ADCETRIS® (brentuximab vedotin) in combination with lenalidomide and rituximab...
Merck Successfully Acquires Harpoon Therapeutics, Inc.
Merck has successfully completed the acquisition of Harpoon Therapeutics, Inc., making Harpoon a wholly-owned subsidiary of Merck. As a...
Digital Health Technologies: New Era in Clinical Research
Digital health technologies (DHTs) are revolutionizing the landscape of clinical research, pushing us toward more innovative and patient-centered trial...
Remarkable Edge in Cancer Vaccine Treatment: New Hope
In this interview, we engage with Andrew Allen, a pioneering force in the field of immunotherapy and the co-founder...
Viiv Healthcare Presents Promising Cabenuva Data at CROI
ViiV Healthcare has announced promising interim data from the LATITUDE phase III trial, presented at the CROI 2024. The...
Gilead & Merck’s Phase 2 Data Show Promise for Oral Weekly HIV Regimen
Gilead Sciences and Merck (MSD outside the U.S. and Canada) have shared promising Phase 2 clinical study results for...
Gilead & Merus Team Up for Groundbreaking T-Cell Engagers
Gilead Sciences, Inc. and Merus N.V. have entered into a research collaboration to develop novel dual tumor-associated antigen (TAA)...
EU Validates Datopotamab Apps for Lung & Breast Cancer
The European Medicines Agency (EMA) has validated two marketing authorization applications (MAAs) for Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan,...
Real-World Data Back Veklury for Hospitalized COVID-19 Patients
Gilead Sciences revealed new data from three retrospective studies that suggest its antiviral drug Veklury (remdesivir) not only reduces...